Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/2/2021 | Buy → Neutral | BTIG | |
| 7/30/2021 | $23.00 → $28.00 | Buy → Hold | Canaccord Genuity |
4 - MISONIX INC (0000880432) (Issuer)
4 - MISONIX INC (0000880432) (Issuer)
4 - MISONIX INC (0000880432) (Issuer)
RW - MISONIX INC (0000880432) (Filer)
15-12B - MISONIX INC (0000880432) (Filer)
8-K - MISONIX INC (0000880432) (Filer)
BTIG downgraded Misonix from Buy to Neutral
Canaccord Genuity downgraded Misonix from Buy to Hold and set a new price target of $28.00 from $23.00 previously
DURHAM, N.C. and FARMINGDALE, N.Y., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, and Misonix, Inc. (NASDAQ:MSON) ("Misonix"), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that enhance clinical outcomes, today announced that the stockholders of Bioventus approved the issuance of shares of Bioventus class A common stock to the stockholders of Misonix in connection with the previously announced Agreement and Plan of Merger, dated July 29, 2021, by and among Bioventus, Misonix and other parties thereto, pursuant to which Misonix will be acquired
DURHAM, N.C. and FARMINGDALE, N.Y., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) and Misonix, Inc. (NASDAQ:MSON) ("Misonix"), today announced an election deadline of 5:00 p.m., New York City Time, on October 25, 2021 (the "Election Deadline") for stockholders of Misonix to elect the form of consideration they wish to receive for their shares of Misonix common stock in connection with the proposed merger of Oyster Merger Sub I, Inc., a newly-formed, wholly-owned subsidiary of Bioventus ("Merger Sub I"), with and into Misonix, immediately followed by the merger of Misonix with and into Oyster Merger Sub II, LLC, another newly-formed, wholly-owned subsidiary of Bioventus ("Me
FARMINGDALE, N.Y., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ:MSON) ("Misonix" or the "Company"), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today reported unaudited financial results for the fiscal 2021 fourth quarter and full fiscal year ended June 30, 2021 as summarized below: Three Months Ended Years Ended June 30, June 30, 2021 2020 2021 2020 Revenue$19,685,141 $13,713,231 $74,024,073 $62,483,651 Gross profit$14,075,377 $9,432,383 $52,636,255 $43,709,483 Gross profit percentage 71.5% 68.8% 71.1% 70.0% Pretax loss$(4,341,201) $(8,495,994) $(14,341,254)$(21,91
FARMINGDALE, N.Y., May 14, 2021 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ:MSON) ("Misonix" or the "Company"), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today announced its Board of Directors has appointed Patrick J. Beyer as an independent member of the Board. Mr. Beyer joined the Board on May 12, 2021. "Pat is a highly respected, purpose-driven leader who has a proven, long-term track record of success throughout his career in the healthcare industry," stated Stavros Vizirgianakis, Chief Executive Officer of Misonix. "Pat has been an integral member of ConMed's executive team and his leadership expert
FARMINGDALE, N.Y., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ:MSON) ("Misonix" or the "Company"), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today reported unaudited financial results for the fiscal 2021 fourth quarter and full fiscal year ended June 30, 2021 as summarized below: Three Months Ended Years Ended June 30, June 30, 2021 2020 2021 2020 Revenue$19,685,141 $13,713,231 $74,024,073 $62,483,651 Gross profit$14,075,377 $9,432,383 $52,636,255 $43,709,483 Gross profit percentage 71.5% 68.8% 71.1% 70.0% Pretax loss$(4,341,201) $(8,495,994) $(14,341,254)$(21,91
Significantly Expands TAM and Adds Considerable Scale and Scope in Spine and Lower ExtremityEnhances Surgical Solutions Vertical by Adding Minimally Invasive Ultrasonic Technologies That Improve Clinical OutcomesDeepens Restorative Therapies Vertical by Adding Regenerative Medicine Wound ProductsBioventus and Misonix Management to Host Joint Conference Call Today at 4:30 p.m. Eastern Time DURHAM, N.C. and FARMINGDALE, N.Y., July 29, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus"), a global leader in innovations for active healing, and Misonix, Inc. (NASDAQ:MSON) ("Misonix"), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine
DURHAM, N.C., July 29, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported preliminary financial results for the three months ended July 3, 2021. Preliminary Second Quarter Net Sales: Net Sales of $108 million to $110 million represents 86.2% to 89.7% year-over-year growth and comprises: Net sales from legacy Bioventus Inc. of $96.5 million to $98.0 million, representing organic year-over-year revenue growth* of 66.4% to 69.0%, andNet sales from the acquisition of Bioness Inc. of $11.5 million to $12.0 million. Updated Full-Year 2021 Net Sales Guidance: For the twelve
SC 13G/A - MISONIX INC (0000880432) (Subject)
SC 13G/A - MISONIX INC (0000880432) (Subject)